226 related articles for article (PubMed ID: 31853958)
1. Clinical experience combined with therapeutic drug monitoring of lacosamide.
Svendsen T; Brodtkorb E; Baftiu A; Lossius MI; Nakken KO; Johannessen SI; Johannessen Landmark C
Acta Neurol Scand; 2020 Apr; 141(4):279-286. PubMed ID: 31853958
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic Variability, Efficacy and Tolerability.
Svendsen T; Brodtkorb E; Baftiu A; Burns ML; Johannessen SI; Johannessen Landmark C
Neurochem Res; 2017 Jul; 42(7):2077-2083. PubMed ID: 28349359
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Monitoring of Lacosamide in Japanese Patients With Epilepsy: Clinical Response, Tolerability, and Optimal Therapeutic Range.
Yamamoto Y; Terada K; Araki Y; Fukushima Y; Imai K; Kagawa Y; Takahashi Y
Ther Drug Monit; 2020 Oct; 42(5):754-759. PubMed ID: 32941398
[TBL] [Abstract][Full Text] [Related]
4. Lacosamide in patients with intellectual disability and refractory epilepsy.
Kleist A; Kerling F; Hamer H; Winterholler M
Acta Neurol Belg; 2019 Sep; 119(3):423-430. PubMed ID: 30840220
[TBL] [Abstract][Full Text] [Related]
5. Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: A long-term study of 136 patients.
Böttcher S; Lutz MT; Mayer T
Epilepsia; 2017 Oct; 58(10):1749-1754. PubMed ID: 28804872
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Variability and Clinical Use of Lacosamide in Children and Adolescents in Denmark and Norway.
Larsen Burns M; Nikanorova M; Baftiu A; Borg Rasmussen J; Johannessen SI; Johannessen Landmark C
Ther Drug Monit; 2019 Jun; 41(3):340-347. PubMed ID: 30688870
[TBL] [Abstract][Full Text] [Related]
7. Lacosamide effectiveness and tolerability in patients with drug-resistant epilepsy and severe disability under polytherapy: Therapy optimization as emerging from an observational study.
Pozzi M; Zanotta N; Epifanio R; Baldelli S; Cattaneo D; Clementi E; Zucca C
Epilepsy Behav; 2022 Mar; 128():108598. PubMed ID: 35151192
[TBL] [Abstract][Full Text] [Related]
8. Switching from traditional sodium channel blockers to lacosamide in patients with epilepsy.
Kim DW; Kim HK; Bae EK
Seizure; 2019 Feb; 65():172-175. PubMed ID: 30721874
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: A single-center observational study.
Rosati A; Ilvento L; Rizzi R; Doccini V; Leo MC; Pugi A; De Masi S; Guerrini R
Epilepsia; 2018 May; 59(5):1004-1010. PubMed ID: 29663335
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of immediate switch from sodium channel blockers to Lacosamide.
Talha Özgün O; Kandemir Yılmaz M; Mert Atmaca M; Keskin Güler S; Buluş E; Duman A; Çelebi Ö; Gürses C
Epilepsy Behav; 2023 Aug; 145():109355. PubMed ID: 37473655
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: A cohort study.
Ishikawa N; Eguchi Y; Izumo H; Tateishi Y; Tani H; Kobayashi Y; Okada S
Epilepsy Behav; 2022 Apr; 129():108614. PubMed ID: 35203014
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs.
Neal A; D'Souza W; Hepworth G; Lawn N; Cook M; Nikpour A
Epilepsy Behav; 2018 Mar; 80():25-32. PubMed ID: 29396359
[TBL] [Abstract][Full Text] [Related]
13. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of treatment with lacosamide: Postmarketing experience from the Middle East region.
Arabi M; Alsaadi T; Nasreddine W; Al-Hashel J; Dirani M; Beydoun A
Epilepsy Behav; 2018 Jul; 84():118-121. PubMed ID: 29778846
[TBL] [Abstract][Full Text] [Related]
15. Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort.
McGinnis E; Kessler SK
Epilepsia; 2016 Sep; 57(9):1416-25. PubMed ID: 27430392
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of lacosamide in children and young adults previously treated with other sodium channel blockers.
Suzuki T; Natsume J; Kumai S; Maki Y; Yamamoto H; Numoto S; Narahara S; Kubota T; Tsuji T; Kato T; Yamada K; Maruyama K; Okumura A; Takahashi Y; Kidokoro H
Epilepsy Behav; 2021 Dec; 125():108397. PubMed ID: 34814035
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study.
Del Bianco C; Placidi F; Liguori C; Mari L; Ulivi M; Ornello R; Pisani A; Mercuri NB; Izzi F
Epilepsy Behav; 2019 May; 94():178-182. PubMed ID: 30959275
[TBL] [Abstract][Full Text] [Related]
18. Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: A prospective multicenter study.
Rocamora R; Ley M; Molins A; Toledo M; Sansa G; Bertol V; Becerra JL; Carreño M; Mauri JÁ
Epilepsy Behav; 2018 Feb; 79():87-92. PubMed ID: 29253680
[TBL] [Abstract][Full Text] [Related]
19. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
Contin M; Albani F; Riva R; Candela C; Mohamed S; Baruzzi A
Ther Drug Monit; 2013 Dec; 35(6):849-52. PubMed ID: 23942540
[TBL] [Abstract][Full Text] [Related]
20. Effects of lacosamide and carbamazepine on lipids in a randomized trial.
Mintzer S; Dimova S; Zhang Y; Steiniger-Brach B; De Backer M; Chellun D; Roebling R
Epilepsia; 2020 Dec; 61(12):2696-2704. PubMed ID: 33200428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
